FDA Approves the AVMAPKI™ FAKZYNJA™ Combination Therapy as the First-Ever Treatment for Adult Patients with KRAS-mutated Recurrent Low-Grade Serous Ovarian Cancer

FDA Approves the AVMAPKI™ FAKZYNJA™ Combination Therapy as the First-Ever Treatment for Adult Patients with KRAS-mutated Recurrent Low-Grade Serous Ovarian Cancer#FDA #Approves #AVMAPKI #FAKZYNJA #Combination #Therapy #FirstEver #Treatment #Adult #Patients #KRASmutated #Recurrent #LowGrade #Serous #Ovarian #Cancer